Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Platelet transfusions are frequent in the Intensive Care Unit (ICU), either as prophylaxis against bleeding complications or as treatment for bleeding. The European Society of Intensive Care Medicine guidelines for ICU patients generally recommend not using prophylactic platelet transfusions unless the platelet count falls below 10 × 10 cells/L in non-bleeding patients and make no recommendation for platelet transfusion threshold in non-massively bleeding patients with thrombocytopenia. Therefore, the decision to transfuse platelets is often left to clinical assessment by the treating physician. This study aims to describe current platelet transfusion preferences among ICU physicians.

Methods: An online, anonymous survey consisting of 43 items was produced in two languages (French and English) and distributed by investigators in the Nine-I research network to ICU physicians in Europe and the United States of America. The survey evaluated platelet transfusion practices in ICU patients with and without bleeding, the presence of local guidelines, and factors influencing the decisions to transfuse platelets. Only completed surveys were analysed.

Results: We received 997 surveys completed by ICU physicians. Overall, there was large heterogeneity in platelet transfusion practices between and within countries. In non-bleeding, thrombocytopenic medical ICU patients, most would transfuse prophylactic platelets at a platelet count threshold of 10 × 10 cells/L. Thirty percent would change their strategy in patients with bone marrow failure and either be more liberal (60%; 95% Confidence Limits 0.54, 0.66), more restrictive (31%; 0.26,0.36) or seek assistance. Higher thresholds were preferred in surgical patients, prior to procedures and in patients with bleeding. Only 173 (17%; 0.15,0.19) responded that they were confident about the clinical indications every time they prescribed a platelet transfusion. As for existing guidelines, only 123 (12%; 0.10,0.15) responded that they always read them. Colleagues' attitudes and departmental culture were important influencers on transfusion practice.

Conclusion: Platelet transfusion practice in the ICU is heterogeneous, both between and within countries; guidelines are often not used, and there is often uncertainty about the clinical indication.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237844PMC
http://dx.doi.org/10.1186/s13613-025-01494-4DOI Listing

Publication Analysis

Top Keywords

platelet transfusion
32
platelet
12
intensive care
12
icu patients
12
transfusion practice
8
care unit
8
transfusion
8
platelet transfusions
8
icu
8
patients
8

Similar Publications

Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in patients with malignant lymphoma (ML) who underwent allogeneic hematopoietic stem cell transplantation (alloHCT). The cohort included patients with ML who underwent first alloHCT from 2007 to 2021.

View Article and Find Full Text PDF

Platelet transfusion not only attenuates bleeding and promotes hemostasis but also plays a critical role in vascular stability and endothelial barrier integrity. Under amotosalen-UVA pathogen reduction of platelets, pathogen nucleic acids undergo adduction, which prevents their replication and greatly reduces the risk of transfusion-transmitted infections. Although pathogen-reduced (PR) platelets are increasing in clinical use, the physiologic effects of pathogen reduction on platelets, particularly its impact on platelet-endothelial interactions, have yet to be described.

View Article and Find Full Text PDF

Introduction: Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).

Methods: We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018.

View Article and Find Full Text PDF

Integrin β3 dysregulation impairs megakaryopoiesis and microparticle production via disrupting ROCK-dependent cytoskeletal dynamics.

J Thromb Haemost

September 2025

Key Laboratory of Thrombosis and Hemostasis of National Health Commission, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China; Engineering Center of Hematological Disease of Ministry of Education, Cyrus Tang Hematology Center, Collaborative Innovation

Background: Megakaryocyte (MK) fragmentation into proplatelets (PPTs) and microparticles (MKMPs) is well established, yet the mechanisms underlying MKMP generation remain unclear.

Objectives: In order to investigate the role of integrin β3 and cytoskeletal dynamics during megakaryopoiesis and explore potential therapeutic targets for thrombocytopenia.

Methods: Proplatelet formation and MKMP release were evaluated both in vivo and in vitro under integrin β3 receptor impaired environment.

View Article and Find Full Text PDF

Relieving platelet inhibition using a novel bi-specific antibody: A novel approach for circumventing the platelet storage lesion.

J Thromb Haemost

September 2025

Blood Research Institute, Versiti, Milwaukee, WI; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI; Department of Cell biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI. Electronic address:

Background: Human platelets experience structural and functional deterioration during extra-corporeal storage at either room temperature or in the cold, impairing their reactivity and diminishing their hemostatic effectiveness following transfusion. PECAM-1 is an inhibitory receptor on platelets that exerts its inhibitory effects via phosphorylation of tyrosine residues that lie within its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The purpose of this investigation was to attempt to restore platelet reactivity by impairing the inhibitory activity of PECAM-1.

View Article and Find Full Text PDF